Goprelto Patent Expiration

Goprelto is a drug owned by Noden Pharma Dac. It is protected by 12 US drug patents filed from 2018 to 2021 out of which none have expired yet. Goprelto's patents have been open to challenges since 14 December, 2021. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 07, 2037. Details of Goprelto's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10016407 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US9867815 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10413505 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10420760 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10149843 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10933060 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10973811 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10987347 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10894012 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10857095 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US10231961 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active
US11040032 Pharmaceutical compositions and methods of using the same
Feb, 2037

(12 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Goprelto's patents.

Given below is the list of recent legal activities going on the following patents of Goprelto.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 03 Jul, 2024 US10894012
Payment of Maintenance Fee, 4th Year, Large Entity 22 May, 2024 US10857095
Payment of Maintenance Fee, 4th Year, Large Entity 08 Mar, 2023 US10420760 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 01 Mar, 2023 US10413505
Payment of Maintenance Fee, 4th Year, Large Entity 14 Sep, 2022 US10231961
Payment of Maintenance Fee, 4th Year, Large Entity 13 Jun, 2022 US10016407 (Litigated)
Surcharge for Late Payment, Large Entity 13 Jun, 2022 US10016407 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 09 Jun, 2022 US10149843
Maintenance Fee Reminder Mailed 28 Feb, 2022 US10016407 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 14 Jan, 2022 US9867815 (Litigated)


FDA has granted several exclusivities to Goprelto. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Goprelto, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Goprelto.

Exclusivity Information

Goprelto holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Goprelto's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 14, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Goprelto is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Goprelto's family patents as well as insights into ongoing legal events on those patents.

Goprelto's Family Patents

Goprelto has patent protection in a total of 1 countries. It has a significant patent presence in the US with 100.0% of its patents being US patents. Click below to unlock the full patent family tree for Goprelto.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Goprelto's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 07, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Goprelto Generics:

There are no approved generic versions for Goprelto as of now.

Alternative Brands for Goprelto

Goprelto which is used for local anesthesia of mucous membranes in various patient populations., has several other brand drugs in the same treatment category and using the same active ingredient (Cocaine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Omnivium Pharms
Numbrino

(uses Cocaine Hydrochloride)

Used for local anesthesia in patients with uveal melanoma and hepatic metastases, as well as those with hepatic or renal impairment.





About Goprelto

Goprelto is a drug owned by Noden Pharma Dac. It is used for local anesthesia of mucous membranes in various patient populations. Goprelto uses Cocaine Hydrochloride as an active ingredient. Goprelto was launched by Noden Pharma in 2017.

Approval Date:

Goprelto was approved by FDA for market use on 14 December, 2017.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Goprelto is 14 December, 2017, its NCE-1 date is estimated to be 14 December, 2021.

Active Ingredient:

Goprelto uses Cocaine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Cocaine Hydrochloride ingredient

Treatment:

Goprelto is used for local anesthesia of mucous membranes in various patient populations.

Dosage:

Goprelto is available in solution form for nasal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
4% SOLUTION Prescription NASAL